Eisai Realigns U.S. Operations

WOODCLIFF LAKE, N.J., April 9, 2015 /PRNewswire/ -- Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., today announced plans to realign its operations in the United States. As part of this restructuring, Eisai Inc. will reduce its workforce by approximately 25 percent across various U.S. functions. This realignment supports Eisai's desire to create a more efficient and focused organization.
 
"The actions we are taking will ensure Eisai stays competitive in a rapidly changing business environment," said Yuji Matsue, Chairman and CEO of Eisai Inc. "Eisai remains fully committed to the U.S. market and will continue to serve the needs of patients and their families by developing and marketing important new treatments that help to satisfy unmet medical needs. Through this realignment, we will be able to redeploy our resources to support the development of our priority late-stage compounds and our current product portfolio."
 
The new structure is expected to be in place by May 1, 2015. Eisai's U.S. operations include research and development, manufacturing, sales and marketing, and administrative functions. The company does not have plans to close any of its main offices or facilities.
 
"This decision was difficult," said Shaji Procida, President and COO of Eisai Inc. "We are grateful to our colleagues, each of whom has played an important role in helping us fulfill our human health care (hhc) mission of bringing important new medicines to patients. We are aware of the impact that our reorganization will have on some employees and will work with them to ensure that their transition is as smooth as possible."   
 
Eisai Inc. 
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US.
 
Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.
 
Eisai Co., Ltd.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including oncology and neurology.
 
As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.
 
For more information about Eisai Co., Ltd., please visit www.eisai.com.    
 
Media Inquiries
Investor Inquiries
Suzanne Grogan
Alex Scott
Eisai Inc.
Eisai Inc.
201-746-2083
201-746-2177
SOURCE Eisai Inc.
 

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Sen. Elizabeth Warren asked the SEC to probe Kodak trades made before the Trump administration unveiled their drug supply deal—and $765M in funding.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.